Zobrazit v EDS

A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management

Uloženo v:
Podrobná bibliografie
Název: A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management
Autoři: Andersson, Nadine G., Rathe, Mathias, Molle, Ingolf, Jarvis, Kirsten Brunswig, Hoffmann, Marianne, Huurre, Anu, Joelsson, Joel, Albertsen, Birgitte Klug, Lohi, Olli, Långström, Satu, Overgaard, Ulrik, Trakymiene, Sonata Saulyte, Vepsäläinen, Kaisa, Vogt, Hartmut, 1970, Ranta, Susanna
Zdroj: British Journal of Haematology. 199(1):117-121
Témata: ALL, antithrombin, childhood leukaemia, paediatric haemostasis, paediatric thrombosis, thrombosis
Popis: Patients undergoing treatment for acute lymphoblastic leukaemia (ALL) are at risk of coagulopathy, especially thromboembolism. We conducted a survey on practices in the assessment and management of coagulopathy during the new ALLTogether protocol in 29 (17 paediatric, 12 adult) Nordic and Baltic cancer centres. While 92% of adult centres used thromboprophylaxis with low-molecular-weight heparin, no paediatric centre did. Almost all providers performed baseline coagulation studies, but only 59% continued the assessment. Fibrinogen replacement was conducted in 59%, and antithrombin replacement in 28% of the centres. The survey highlights the need for guidelines in the management of coagulopathy during ALL therapy.
Popis souboru: electronic
Přístupová URL adresa: https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-187301
https://liu.diva-portal.org/smash/get/diva2:1688224/FULLTEXT01.pdf
Databáze: SwePub
Popis
Abstrakt:Patients undergoing treatment for acute lymphoblastic leukaemia (ALL) are at risk of coagulopathy, especially thromboembolism. We conducted a survey on practices in the assessment and management of coagulopathy during the new ALLTogether protocol in 29 (17 paediatric, 12 adult) Nordic and Baltic cancer centres. While 92% of adult centres used thromboprophylaxis with low-molecular-weight heparin, no paediatric centre did. Almost all providers performed baseline coagulation studies, but only 59% continued the assessment. Fibrinogen replacement was conducted in 59%, and antithrombin replacement in 28% of the centres. The survey highlights the need for guidelines in the management of coagulopathy during ALL therapy.
ISSN:00071048
13652141
DOI:10.1111/bjh.18397